BRAIN and NERVE－神経研究の進歩74巻5号

2022年05月発行

増大特集 次の一手—神経筋疾患難治例をどのように治療するか

3種類のmainstay治療に反応しないCIDP—適切な寛解導入療法と治療効果判定

著者： 海田賢一¹

所属機関： ¹埼玉医科大学総合医療センター脳神経内科

ページ範囲：P.510 - P.516

文献概要

慢性炎症性脱髄性多発根ニューロパチー（CIDP）はheterogeneousな病態を持つ疾患であり，mainstay治療への反応性もCIDPの病型で異なる。CIDPの病型，治療法の特性，患者背景を基に治療法を選択する。Mainstay治療抵抗性CIDPでは，寛解導入療法が適切に行われ，客観的指標で治療効果が適切に評価されたかどうかを確認する。治療抵抗性multifocal CIDP，distal CIDPでは慎重な鑑別診断が必要である。

参考文献

1）Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society: first revision. J Peripher Nerv Syst 15: 1-9, 2010 / Eur J Neurol 17: 356-363, 2010

2）Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, et al: European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst 26: 242-268, 2021 / Eur J Neurol 28: 3556-3583, 2021

3）日本神経学会（監修）: 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン2013. 南江堂, 東京, 2013

4）Kuwabara S, Isose S, Mori M, Mitsuma S, Sawai S, et al: Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86: 1054-1059, 2015

5）Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, et al: Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP database. J Neurol Neurosurg Psychiatry 90: 125-132, 2019

6）Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, et al: Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11: 493-502, 2012

7）Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, et al: Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase Ⅲ trial. J Neurol Neurosurg Psychiatry 88: 832-838, 2017

8）Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, et al: Efficacy and safety of IVIG in CIDP: combined data of the PRIMA and PATH studies. J Peripher Nerv Syst 24: 48-55, 2019

9）van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, et al: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9: 245-253, 2010

10）Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN: Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78: 1079-1084, 2012

11）Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, et al: Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86: 729-734, 2015

12）Muley SA, Jacobsen B, Parry G, Usman U, Ortega E, et al: Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 61: 575-579, 2020

13）Godil J, Barrett MJ, Ensrud E, Chahin N, Karam C: Refractory CIDP: clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci 418: 117098, 2020［doi: 1016/j.jns.2020.117098］

14）Dalakas MC: IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm 9: e1116, 2021［doi: 10.1212/NXI.0000000000001116］

15）Fatehi F, Okhovat AA, Panahi A, Ziaaddini B, Rajabally YA, et al: Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst 26: 469-474, 2021

16）Hu J, Sun C, Lu J, Zhao C, Lin J: Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. J Neurol, 2021 [online ahead of print]［doi: 10.1007/s00415-021-10646-y］

17）Kaplan A, Brannagan TH 3rd: Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 55: 476-482, 2017

18）van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, et al: Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 24: 187-194, 2019

19）Capodivento G, De Michelis C, Carpo M, Fancellu R, Schirinzi E, et al: CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. J Neurol Neurosurg Psychiatry 92: 303-310, 2021